The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kozyreva A.A.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Bembeeva R.Ts.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Druzhinina E.S.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Zavadenko N.N.

Pirogov Russian National Research Medical University

Guillain—Barre syndrome in children

Authors:

Kozyreva A.A., Bembeeva R.Ts., Druzhinina E.S., Zavadenko N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9‑2): 20‑32

DOI: 10.17116/jnevro202312309220

Read: 4256 times

Download PDF (RU)
Contact the author
Table of contents

GUILLAIN—BARRE SYNDROME IN CHILDREN
GUILLAIN—BARRE SYNDROME IN CHILDREN

To cite this article:

Kozyreva AA, Bembeeva RTs, Druzhinina ES, Zavadenko NN. Guillain—Barre syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(9‑2):20‑32. (In Russ.)
https://doi.org/10.17116/jnevro202312309220

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Guillain—Barré syndrome (GBS) is an immune-mediated disease of the peripheral nervous system that can occur in both children and adults. The classic presentation of GBS is characterized by progressive symmetrical, ascending muscle weakness. Patients with GBS require meticulous monitoring due to the risk of bulbar syndrome, respiratory failure and autonomic dysfunction, which can be life-threatening. Early diagnosis and timely prescription of pathogenetic therapy for GBS are particularly important, especially in young children. Meanwhile, the spectrum of disorders covered by GBS has expanded significantly; its eponym is now designate any variant of acute dysimmune polyneuropathy, and its atypical forms pose a serious diagnostic problem for clinicians. This review article provides an analysis of the data available in the medical literature on GBS in children and discusses the tactics for diagnosing and managing patients with GBS, taking into account the Russian and European clinical recommendations.

Keywords:

pediatric Guillain—Barre syndrome
pediatric acute inflammatory demyelinating polyneuropathy
polyradiculoneuropathy
flaccid paralysis

Authors:

Kozyreva A.A.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Bembeeva R.Ts.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Druzhinina E.S.

Pirogov Russian National Research Medical University;
Russian Children’s Clinical Hospital

Zavadenko N.N.

Pirogov Russian National Research Medical University

Received:

18.10.2023

Accepted:

20.10.2023

Close metadata

References:

  1. Chung A, Deimling M. Guillain-Barré Syndrome. Ped Rev. 2018;39(1):53-54.  https://doi.org/10.1542/pir.2017-0189
  2. Evans OB, Vedanarayanan V. Guillain-Barré syndrome. Ped Rev. 1997;18(1):10-16.  https://doi.org/10.1542/pir.18-1-10
  3. Kalra V, Sankhyan N, Sharma S, et al. Outcome in childhood Guillain-Barré syndrome. Indian J Ped. 2009;76(8):795-799.  https://doi.org/10.1007/s12098-009-0125-y
  4. Guillain G, Barré JA, Strohl A. Sur un syndrome de radiculonevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineaux. Bulletins et Mémoires de la Société Médicale des Hôpitaux de Paris. 1916;40:1462-1470.
  5. Holmes G. Acute febrile polyneuritis. Br Med J. 1917;2(2950):37-39.  https://doi.org/10.1136/bmj.2.2950.37
  6. Bradford JR, Bashford EF, Wilson JA. Acute infective polyneuritis. The Quarterly Journal of Medicine. 1918;12:88. 
  7. Debré R, Thieffry S. Remarques sur le Syndrome de Guillain-Barré chez l’Enfant, Archives Francaises de Pediatrie. 1951;8:357-364. 
  8. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). NEJM. 1956;255(2):57-65.  https://doi.org/10.1056/NEJM195607122550201
  9. Bickerstaff ER. Brainstem encephalitis (Bickerstaff’s encephalitis). Handbook of clinical neurology. 1978;34:605-609. 
  10. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arc Neurol. 1986;43(11):1150-1152. https://doi.org/10.1001/archneur.1986.00520110044012
  11. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43(10):1911-1917. https://doi.org/10.1212/wnl.43.10.1911
  12. McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593-597.  https://doi.org/10.1016/0140-6736(91)90606-p
  13. Kuroki S, Haruta T, Yoshioka M, et al. Guillain-Barré syndrome associated with Campylobacter infection. Ped Inf Dis J. 1991;10(2):149-151.  https://doi.org/10.1097/00006454-199102000-00014
  14. Monier-Vinard M. Guillain-Barré syndrome. Revue Neurologique. 1925;32(2):761. 
  15. Aylett P. Five cases of acute infective polyneuritis (Guillain-Barré syndrome) in children. Arch Dis Child. 1954;29(148):531-536.  https://doi.org/10.1136/adc.29.148.531
  16. Merrill RE, Fredrickson D. Landry-Guillain-Barré syndrome. J Ped. 1959;54(6):816-822.  https://doi.org/10.1016/S0022-3476(59)80152-9
  17. Cantalini C. Guillain-Barre polyradiculoneuritis in a 2-month-old infant treated with dexamethasone. Minerva Pediatrics. 1960;12:1322-1325.
  18. Vega-Castro R, Garcia-Dominguez M, Tostado-Morales E. Guillain-Barré syndrome. A Case Report of Guillain-Barre Syndrome in an Eleven-Month Infant. J Med Cases. 2021;12(3):115-118.  https://doi.org/10.14740/jmc3638
  19. Eden AN. Guillain-Barre syndrome in a six-month-old infant. Am J Dis Chil. 1961;102:224-227.  https://doi.org/10.1001/archpedi.1961.02080010226012
  20. Vasconcelos A, Abecasis F, Monteiro R, et al. 3-month-old baby with H1N1 and Guillain-Barre syndrome. Br Med J. 2012;45(87):56-59.  https://doi.org/10.1136/bcr.12.2011.5462
  21. Kishore P, Sharma PK, Saikia B, Khilnani P. Guillain- Barre syndrome masquerading as acute respiratory failure in an infant. J Ped Neurosci. 2015;10(4):399-400.  https://doi.org/10.4103/1817-1745.174461
  22. Akarcan SE, Isguder R, Yilmaz U, et al. Guillain-Barre syndrome in a 7-month-old boy successfully applied plasma exchange. Transfus Apheresis Sci. 2016;54(1):139-143.  https://doi.org/10.1016/j.transci.2016.01.001
  23. Mishra S, Mondal D, Mahar J, et al. Guillain-Barre Syndrome (GBS) in a 2-month-old infant: a case report. Schol J Appl Med Sci. 2017;5(3B):844-845. 
  24. Luijckx GJ, Vles J, de Baets M, et al. Guillain-Barré syndrome in mother and newborn child. Lancet. 1997J;349(9044):27.  https://doi.org/10.1016/s0140-6736(97)24001-8
  25. Shahrizaila N, Lehmann H, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228. https://doi.org/10.1016/S0140-6736(21)00517-1
  26. Yuki N, Hartung HP. Guillain-Barré syndrome. NEJM. 2012;366(24):2294-2304. https://doi.org/10.1056/NEJMra1114525
  27. McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150-163.  https://doi.org/10.1159/000184748
  28. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939-950.  https://doi.org/10.1016/S1474-4422(08)70215-1
  29. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-133.  https://doi.org/10.1159/000324710
  30. Van den Berg B, Walgaard C, Drenthen J, et al. Guillain-Barre syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Rev Neurol. 2014;10(8):469-482.  https://doi.org/10.1038/nrneurol.2014.121
  31. Islam Z, Jacobs BC, Islam MB, et al. High incidence of Guillain-Barré syndrome in children, Bangladesh. Emerg Infect Dis. 2011;17(7):1317-1318. https://doi.org/10.3201/eid1707.101999
  32. Doets AY, Verboon C, van den Berg B, et al.; IGOS Consortium. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866-2877. https://doi.org/10.1093/brain/awy232
  33. van Doorn PA. Guillain-Barré syndrome, Editor(s): Y.A. Rajabally, Dysimmune Neuropathies, Academic Press; 2020;5-29.  https://doi.org/10.1016/B978-0-12-814572-2.00002-9
  34. Hicks CW, Kay B, Worley SE, et al. A clinical picture of Guillain-Barré syndrome in children in the United States. J Child Neurol. 2010;25(12):1504-1510. https://doi.org/10.1177/0883073810370481
  35. Nachamkin I, Barbosa PA, Ung H, et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population. Neurology. 2007;69:1665-1671. https://doi.org/10.1212/01.wnl.0000265396.87983.bd
  36. Lyu RK, Tang LM, Cheng SY, et al. Guillain- Barre ́ syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry. 1997;63:494-500.  https://doi.org/10.1136/jnnp.63.4.494
  37. Lin JJ, Hsia SH, Wang HS, et al. Clinical variants of Guillain-Barre ́ syndrome in children. Pediatr Neurol. 2012;47:91-96.  https://doi.org/10.1016/j.pediatrneurol.2012.05.011
  38. Fujii K, Shiohama T, Uchida T, et al. Nationwide survey of childhood Guillain-Barré syndrome, Fisher syndrome, and Bickerstaff brainstem encephalitis in Japan. Brain Dev. 2023;45(1):16-25.  https://doi.org/10.1016/j.braindev.2022.09.007
  39. Nagasawa K, Kuwabara S, Misawa S, et al. Electrophysiological subtypes and prognosis of childhood Guillain-Barre ́ syndrome in Japan. Muscle Nerve. 2006;33:766-770.  https://doi.org/10.1002/mus.20520
  40. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33(4):333-342.  https://doi.org/10.1002/ana.410330402
  41. Visser LH, Van der Meché FG, Van Doorn PA, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain. 1995;118(Pt 4):841-847.  https://doi.org/10.1093/brain/118.4.841
  42. Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain-Barré syndrome: a reappraisal. Ann Neurol. 1999;46(5):701-707.  https://doi.org/10.1002/1531-8249(199911)46:5<701::aid-ana4>3.0.co;2-7
  43. Reisin RC, Cersósimo R, García Alvarez M, et al. Acute «axonal» Guillain-Barré syndrome in childhood. Muscle Nerve. 1993;16(12):1310-1316. https://doi.org/10.1002/mus.880161207
  44. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597-605.  https://doi.org/10.1093/brain/118.3.597
  45. Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000;48(4):624-631.  https://doi.org/10.1002/1531-8249(200010)48:4<624::AID-ANA9>3.0.CO;2-O
  46. Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-106.  https://doi.org/10.1111/j.1600-0404.2004.00272.x
  47. Arnason GBW. Acute inflammatory demyelinating polyneuropathy. In: Dyek PK, Griffin JW, Low PA, Poduslo JF, eds. Peripheral neuropathy. Philadelphia: Saunders; 1993;1437-1497.
  48. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104-1106. https://doi.org/10.1212/wnl.56.8.1104
  49. Koga M, Kusunoki S, Kaida K, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry. 2012;83:1210-1215. https://doi.org/10.1136/jnnp-2012-303060
  50. Santoro JD, Lazzareschi DV, Campen CJ, et al. Pediatric Bickerstaff brainstem encephalitis: a systematic review of literature and case series. J Neurol. 2018;265:141-150.  https://doi.org/10.1007/s00415-017-8684-8
  51. Papri N, Islam Z, Leonhard SE, et al. Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17(5):285-296.  https://doi.org/10.1038/s41582-021-00467-y
  52. Krauer F, Riesen M, Reveiz L, et al.; WHO Zika Causality Working Group. Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain-Barré Syndrome: Systematic Review. PLoS Med. 2017;14(1):e1002203. https://doi.org/10.1371/journal.pmed.1002203
  53. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. NEJM. 1995;333(21):1374-1379. https://doi.org/10.1056/NEJM199511233332102
  54. Hao Y, Wang W, Jacobs BC, et al. Antecedent infections in Guillain-Barré syndrome: a single-center, prospective study. Ann Clin Transl Neurol. 2019;6(12):2510-2517. https://doi.org/10.1002/acn3.50946
  55. McCarthy N, Giesecke J. Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol. 2001;153(6):610-614.  https://doi.org/10.1093/aje/153.6.610
  56. Vellozzi C, Iqbal S, Broder K. Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis. 2014;58(8):1149-1155. https://doi.org/10.1093/cid/ciu005
  57. Tam CC, O’Brien SJ, Petersen I, et al. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS One. 2007;2(4):e344. https://doi.org/10.1371/journal.pone.0000344
  58. Orlikowski D, Porcher R, Sivadon-Tardy V, et al. Guillain-Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52(7):837-844.  https://doi.org/10.1093/cid/cir074
  59. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110-1115. https://doi.org/10.1212/wnl.51.4.1110
  60. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531-1539. https://doi.org/10.1016/S0140-6736(16)00562-6
  61. World Health Organization. WHO statement on the 2nd meeting of IHR Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Accessed on March 09, 2016. https://www.who.int/mediacentre/news/statements/2016/2nd-emergency-committee-zika/en/
  62. Haidy El, Mohamed YE, Eman HE. Characteristics of COVID and post COVID polyneuropathies in adults and pediatrics: an Egyptian sample. Egypt J Neurol Psychiatry Neurosurg. 2021;57:178.  https://doi.org/10.1186/s41983-021-00435-9
  63. Gutiérrez-Ortiz C, Méndez-Guerrero A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5):601-605.  https://doi.org/10.1212/WNL.0000000000009619
  64. Barroso E, Tuta-Quintero E, Olivella J, et al. Guillain Barré syndrome in the paediatric population. Consequence of active infection or long Covid? Rev Colomb Reumatol. 2022;29(4):335-346.  https://doi.org/10.1016/j.rcreue.2023.01.001
  65. Geurtsvankessel CH, Islam Z, Mohammad QD, et al. Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis. 2013;57(9):1369-1370. https://doi.org/10.1093/cid/cit512
  66. Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae triggering the Guillain-Barré syndrome: A case-control study. Ann Neurol. 2016;80(4):566-580.  https://doi.org/10.1002/ana.24755
  67. Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain. 2000;123(Pt 10):2171-2178. https://doi.org/10.1093/brain/123.10.2171
  68. Baxter R, Bakshi N, Fireman B, et al. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013;57(2):197-204.  https://doi.org/10.1093/cid/cit222
  69. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006;166(12):1301-1304. https://doi.org/10.1001/archinte.166.12.1301
  70. Greene SK, Rett MD, Vellozzi C, et al. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. 2013;8(6):e67185. https://doi.org/10.1371/journal.pone.0067185
  71. Woo EJ, Mba-Jonas A, Dimova RB, et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. JAMA. 2021;326(16):1606-1613. https://doi.org/10.1001/jama.2021.16496
  72. Hanson KE, Goddard K, Lewis N, et al. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink. JAMA Netw Open. 2022;5(4):e228879. https://doi.org/10.1001/jamanetworkopen.2022.8879
  73. Janssen JBE, Leow TYS, Herbschleb KH, et al. Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature. J Immunother. 2021;44(7):276-282.  https://doi.org/10.1097/CJI.0000000000000364
  74. Li Y, Zhang X, Zhao C. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. Biomed Res Int. 2021;2021:9800488. https://doi.org/10.1155/2021/9800488
  75. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Nat Compr Cancer Net. 2019;17(3):255-289.  https://doi.org/10.6004/jnccn.2019.0013
  76. Brahmer JR, Lacchetti C, Schneider B, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714-1768. https://doi.org/10.1200/JCO.2017.77.6385
  77. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv119-iv142. https://doi.org/10.1093/annonc/mdx225
  78. Lu JL, Sheikh KA, Wu HS, et al. Physiologic-pathologic correlation in Guillain-Barré syndrome in children. Neurology. 2000;54(1):33-39.  https://doi.org/10.1212/wnl.54.1.33
  79. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39(5):625-635.  https://doi.org/10.1002/ana.410390512
  80. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol. 1996;25(1):33-51.  https://doi.org/10.1007/BF02284784
  81. Uncini A, Kuwabara S. Nodopathies of the peripheral nerve: an emerging concept. J Neurol Neurosurg Psychiatry. 2015;86(11):1186-1195. https://doi.org/10.1136/jnnp-2014-310097
  82. Wakerley BR, Yuki N. Pharyngeal-cervical-brachial variant of Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2014;85(3):339-344.  https://doi.org/10.1136/jnnp-2013-305397
  83. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol. 1995;38(5):809-816.  https://doi.org/10.1002/ana.410380516
  84. Estublier B, Colineaux H, Arnaud C, et al. Long-term outcomes of paediatric Guillain-Barré syndrome. Dev Med Child Neurol. 2023 Jul 27.  https://doi.org/10.1111/dmcn.15693
  85. Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33-43.  https://doi.org/10.1093/brain/awt285
  86. Chakraborty T, Kramer CL, Wijdicks EFM, et al. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care. 2020;32(1):113-120.  https://doi.org/10.1007/s12028-019-00781-w
  87. Korinthenberg R, Schessl J, Kirschner J. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study. Neuropediatrics. 2007;38(1):10-17.  https://doi.org/10.1055/s-2007-981686
  88. Guisset F, Ferreiro C, Voets S, et al. Anti-GQ1b antibody syndrome presenting as acute isolated bilateral ophthalmoplegia: Report on two patients and review of the literature. Eur J Paediatr Neurol. 2016;20(3):439-443.  https://doi.org/10.1016/j.ejpn.2016.02.002
  89. Vanden Eijnden S, Borza D, Caudron V, Cavatorta E. Isolated 6th nerve palsy in a child associated with asymptomatic Chlamydia pneumoniae infection and elevated anti-GQ1b antibody. Eur J Pediatr. 2001;160(6):400.  https://doi.org/10.1007/s004310100742
  90. Kuroki S, Saida T, Nukina M, et al. Three patients with ophthalmoplegia associated with Campylobacter jejuni. Pediatr Neurol. 2001;25(1):71-74.  https://doi.org/10.1016/s0887-8994(01)00281-8
  91. Sato K, Yoshikawa H. Bilateral abducens nerve paresis associated with anti-GQ1b IgG antibody. Am J Ophthalmol. 2001;131(6):816-818.  https://doi.org/10.1016/s0002-9394(00)00956-9
  92. Weber P, Regeniter A, Kaiser HJ. Acute ophthalmoparesis in a child with anti-GQ1 b IgG antibody. Neuropediatrics. 2003;34(5):274-275.  https://doi.org/10.1055/s-2003-43253
  93. Jindal G, Parmar VR, Gupta VK. Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G. Pediatr Neurol. 2009;41(6):451-452.  https://doi.org/10.1016/j.pediatrneurol.2009.07.008
  94. Kauser H, Jain P, Sharma S, Aneja S. Complete bilateral ophthalmoplegia with unilateral facial palsy in a child with anti-GQ1b syndrome. Indian J Pediatr. 2015;82(2):192-194.  https://doi.org/10.1007/s12098-014-1514-4
  95. Morosini A, Burke C, Emechete B. Polyneuritis cranialis with contrast enhancement of cranial nerves on magnetic resonance imaging. J Paediatr Child Health. 2003;39(1):69-72.  https://doi.org/10.1046/j.1440-1754.2003.00074.x
  96. Leonhard SE, Mandarakas MR, Gondim FAA, et el. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683.  https://doi.org/10.1038/s41582-019-0250-9
  97. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;9:CD002063. https://doi.org/10.1002/14651858.CD002063.pub6
  98. Asbury AK, Arnason BGW, Karp HR, et al. Criteria for diagnosis of Guillain- Barré syndrome. Ann Neurol. 1978;3(6):565-566.  https://doi.org/10.1002/ana.410030628
  99. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain- Barré syndrome. Ann Neurol. 1990;27(suppl):21-24.  https://doi.org/10.1002/ana.410270707
  100. Sejvar JJ. Guillain- Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011;29(3):599-612.  https://doi.org/10.1016/j.vaccine.2010.06.003
  101. Roodbol J, de Wit MY, van den Berg B, et al. Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria. J Neurol. 2017;264(5):856-861.  https://doi.org/10.1007/s00415-017-8429-8
  102. Rajabally YA, Durand MC, Mitchell J, et al. Electrophysiological diagnosis of Guillain-Barré syndrome subtype: could a single study suffice? J Neurol Neurosurg Psychiatry. 2015;86(1):115-119.  https://doi.org/10.1136/jnnp-2014-307815
  103. Uncini A, Ippoliti L, Shahrizaila N, et al. Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: criteria sets and sparse linear discriminant analysis. Clin Neurophysiol 2017;128(7):1176-1183. https://doi.org/10.1016/j.clinph.2017.03.048
  104. Arends S, Drenthen J, van den Bergh P. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. Clin Neurophysiol. 2022;138(45):231-240.  https://doi.org/10.1016/j.clinph.2021.12.014
  105. van Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76(4):337-345.  https://doi.org/10.1212/WNL.0b013e318208824b
  106. Arestova AS, Melnik EA, Zaytsev AB, et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Scale for the assessment of disability level in patients with chronic inflammatory demyelinating polyneuropathy: linguocultural ratification In Russia. Neuromuscular Diseases. 2021;11(4):26-33. (In Russ.). https://doi.org/10.17650/2222-8721-2021-11-4-26-33
  107. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology. 2011;76(11):968-975.  https://doi.org/10.1212/WNL.0b013e3182104407
  108. Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol. 2010;67(6):781-787.  https://doi.org/10.1002/ana.21976
  109. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727.  https://doi.org/10.1016/S0140-6736(16)00339-1
  110. Mulkey SB, Glasier CM, El-Nabbout B, et al. Nerve root enhancement on spinal MRI in pediatric Guillain-Barré syndrome. Pediatr Neurol. 2010;43(4):263-269.  https://doi.org/10.1016/j.pediatrneurol.2010.05.011
  111. Elovaara I, Apostolski S, van Doorn P, et al.; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893-908.  https://doi.org/10.1111/j.1468-1331.2008.02246.x
  112. Guillain—Barre syndrome. Clinical recommendations. 2017. (In Russ.).
  113. Bembeeva RTs, Zavadenko NN. Intravenous immunoglobulin in treatment of autoimmune neurological diseases in children. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(8):83-93. (In Russ.). https://doi.org/10.17116/jnevro20151156183-93
  114. Hughes RA, Brassington R, Gunn AA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2016;10(10):CD001446. https://doi.org/10.1002/14651858.CD001446.pub5
  115. Hillyar C, Nibber A. Psychiatric Sequelae of Guillain-Barré Syndrome: Towards a Multidisciplinary Team Approach. Cureus. 2020;12(2):e7051. https://doi.org/10.7759/cureus.7051
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.